Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc. has demonstrated a strong and positive financial trajectory, highlighted by a 17% year-over-year increase in order entry for 2025, driven by robust demand across both its banking and retail segments. The banking segment specifically reported product revenues of $381 million, a notable 20% increase year-over-year, contributing to total banking revenues of $798 million, which rose 16% quarter-over-quarter and 11% year-over-year. Furthermore, the company achieved positive free cash flow for all four quarters in the fiscal year, with fourth-quarter free cash flow growing 5.4% year-over-year to reach $196 million, positioning the firm for sustainable growth leading into 2026 and beyond.

Bears say

Diebold Nixdorf Inc. is facing a negative outlook due to anticipated declines in backlog and earnings, as a sequential decrease in Q4 results is projected alongside typical seasonal trends. While the company is targeting substantial free cash flow generation from 2025 to 2027, there are significant risks including potential adverse impacts from tariff-related costs and supply chain disruptions, which could further affect financial performance. Moreover, the company’s limited liquidity, highlighted by low average daily trading volume, raises concerns about its overall financial stability and ability to navigate market challenges.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Apr 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.